accepted manuscript

ACCEPTED MANUSCRIPT
[11] J.W. Langston, P. Ballard, J.W. Tetrud, I. Irwin, Chronic Parkinsonism in
humans due to a product of meperidine-analog synthesis, Science (New York,
N.Y 219 (1983) 979-980.
[12] G.C. Davis, A.C. Williams, S.P. Markey, M.H. Ebert, E.D. Caine, C.M.
Reichert, I.J. Kopin, Chronic Parkinsonism secondary to intravenous injection
of meperidine analogues, Psychiatry research 1 (1979) 249-254.
[13] J.W. Langston, L.S. Forno, J. Tetrud, A.G. Reeves, J.A. Kaplan, D. Karluk,
Evidence of active nerve cell degeneration in the substantia nigra of humans
years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure, Annals of
neurology 46 (1999) 598-605.
[14] L.S. Forno, L.E. DeLanney, I. Irwin, J.W. Langston, Similarities and
differences between MPTP-induced parkinsonsim and Parkinson's disease.
Neuropathologic considerations, Advances in neurology 60 (1993) 600-608.
[15] P. Hantraye, M. Varastet, M. Peschanski, D. Riche, P. Cesaro, J.C. Willer, M.
Maziere, Stable parkinsonian syndrome and uneven loss of striatal dopamine
fibres following chronic MPTP administration in baboons, Neuroscience 53
(1993) 169-178.
ACCEPTED MANUSCRIPT
[16] M. Varastet, D. Riche, M. Maziere, P. Hantraye, Chronic MPTP treatment
reproduces in baboons the differential vulnerability of mesencephalic
dopaminergic neurons observed in Parkinson's disease, Neuroscience 63
(1994) 47-56.
[17] R. Moratalla, B. Quinn, L.E. DeLanney, I. Irwin, J.W. Langston, A.M.
Graybiel, Differential vulnerability of primate caudate-putamen and
striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine, Proceedings of the National Academy of
41